This prospective , randomized phase III intergroup trial of the Gynecologic Oncology Group and National Cancer Institute of Canada Clinical Trials Group was designed to test the effectiveness and safety of adding the hypoxic cell sensitizer tirapazamine ( TPZ ) to standard cisplatin ( CIS ) chemoradiotherapy in locally advanced cervix cancer .